NewsBenzingaArgenx's FB102 Meets Primary Endpoint In Phase 2 Celiac Disease Study Versus Placebo With No New Safety Signals; Company Will Advance First-In-Class CD122 Inhibitor Into Phase 3 Development Argenx's FB102 Meets Primary Endpoint In Phase 2 Celiac Disease Study Versus Placebo With No New Safety Signals; Company Will Advance First-In-Class CD122 Inhibitor Into Phase 3 Development Benzinga 2026.10.08 05:40 (GMT+0) Open on Benzinga Other news India rejects Elon Musk’s claim of discrimination over Starlink launch Stock Market: Will S&P 500 Open Up or Down Today? Jim Cramer Says SPCX Could Come to Fruition Long Before Tesla After Goldman Sachs Raises Price Target: 'Real Company With Real Numbers' Reported Earlier, HPE Liquid-Cooled Cray XD2000 To Power Mizuho Securities' Expanding Global Strategy And Financial Simulations Trader's short positions on BTC, ETH, SOL, XRP and DOGE all in profit, with unrealized gains of $586,000 Frontdoor: The Margin Expansion Is Permanent (NASDAQ:FTDR)
Jim Cramer Says SPCX Could Come to Fruition Long Before Tesla After Goldman Sachs Raises Price Target: 'Real Company With Real Numbers'
Reported Earlier, HPE Liquid-Cooled Cray XD2000 To Power Mizuho Securities' Expanding Global Strategy And Financial Simulations
Trader's short positions on BTC, ETH, SOL, XRP and DOGE all in profit, with unrealized gains of $586,000
